Annual report 2016 Active Biotech AB (publ)
Active Biotech’s annual report for 2016 is now available on the www.activebiotech.com.
The annual report will only be digitally distributed.
Lund, 18 may 2017
Active Biotech AB (publ)
Tomas Leanderson
Executive director
For further information, please contact:
Hans Kolam, CFO
Tel 046 192044
If Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company focused on the development of drugs for the treatment of neurodegenerative/inflammatory diseases and cancer. Laquinimod, a substance in tablet form with unique immunomodulatory properties, is in phase 2 trials for the treatment of primärprogressiv multiple sclerosis and Huntington’s disease. Anyara, a immunonkologisk substance, has undergone clinical phase 1-2/3 in patients with pancreatic, lung or renal cancer. Furthermore, the conducted commercial activities for the projects tasquinimod, paquinimod and SILC. For further information please visit www.activebiotech.com
Active Biotech AB
Box 724, 220 07 Lund, Sweden
Tel 046-19 20 00
This information is such information that Active Biotech AB is obligated to publish under the Swedish securities market act. The information was submitted for publication 18 may 2017, there is a 14.30.
Annual report 2016 Active Biotech AB (publ)
